Gallacher Capital Management LLC Boosts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Gallacher Capital Management LLC boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,571 shares of the specialty pharmaceutical company’s stock after purchasing an additional 470 shares during the period. Gallacher Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter. AlphaQuest LLC lifted its position in shares of Collegium Pharmaceutical by 3.0% during the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after buying an additional 374 shares during the last quarter. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. Foundry Partners LLC lifted its position in shares of Collegium Pharmaceutical by 3.3% during the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after buying an additional 509 shares during the last quarter. Finally, Caprock Group LLC lifted its position in shares of Collegium Pharmaceutical by 6.7% during the 4th quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after buying an additional 543 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $29.46 on Friday. The stock’s 50-day simple moving average is $30.85 and its 200 day simple moving average is $32.96. The stock has a market capitalization of $927.58 million, a price-to-earnings ratio of 12.70 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analysts Set New Price Targets

COLL has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,961 shares of company stock worth $3,146,634 in the last ninety days. 3.98% of the stock is currently owned by insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.